Hck Inhibitors
1 drugsAbout Hck
Hck (hematopoietic cell kinase) is a Src family non-receptor tyrosine kinase involved in intracellular signaling pathways that regulate cell growth and survival, particularly in hematopoietic cells.
Modulating Hck activity could alter disease progression, but there is currently no genetic evidence directly linking Hck to specific diseases.
Hck is targeted by one FDA-approved small molecule drug, BOSULIF, which is used in an 'other' therapeutic area.
Top Hck Drugs
The competitive landscape for Hck is limited, with only one company, PF PRISM CV, having an approved drug.
The limited competition suggests an opportunity for new entrants to develop novel Hck-targeting therapies.
Hck Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Hck, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
Hck Clinical Trials 34 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Hck. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 11 | 3 | 1 | 79% |
| Phase 2 | 12 | 7 | 3 | 2 | 70% |
| Phase 3 | 5 | 3 | 0 | 2 | 100% |
| Phase 4 | 2 | 0 | 1 | 1 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Hck Drug Approval Timeline (2012 - 2012)
The first and only drug targeting Hck, BOSULIF, was approved in 2012.
The lack of recent approvals suggests a potentially unsaturated market, but also a challenging development landscape.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 16 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Hck. A trial counts if an approved drug acting on Hck is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.